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Outcomes of Treated Human 
Granulocytic Ehrlichiosis Cases
Alan H. Ramsey,*† Edward A. Belongia,‡ Craig M. Gale,‡ and Jeffrey P. Davis†
We conducted a case-control study in Wisconsin to determine whether some patients have long-term
adverse health outcomes after antibiotic treatment for human granulocytic ehrlichiosis (HGE). A standard-
ized health status questionnaire was administered to patients and controls matched by age group and sex.
Consenting patients provided blood samples for serologic testing. Among the 85 previously treated
patients, the median interval since onset of illness was 24 months. Compared with 102 controls, patients
were more likely to report recurrent or continuous fevers, chills, fatigue, and sweats. Patients had lower
health status scores than controls for bodily pain and health relative to 1 year earlier, but there was no sig-
nificant difference in physical functioning, role limitations, general health, or vitality measures. The HGE
antibody titer remained elevated in one patient; two had elevated aspartate aminotransferase levels. HGE
may cause a postinfectious syndrome characterized by constitutional symptoms without functional disabil-
ity or serologic evidence of persistent infection.
uman granulocytic ehrlichiosis (HGE) is a recently iden-
tified tickborne infectious disease caused by a bacterium
species of the genus Ehrlichia that preferentially infects granu-
lar leukocytes (1). HGE was first described in the United
States in 1994 in residents of Wisconsin and Minnesota (2).
During 1986 through 1997, 449 HGE cases were identified in
the United States, mostly in the Northeast and Upper Midwest,
despite limited reporting requirements (3). The primary vector
of HGE is Ixodes scapularis (4), commonly known as the deer
tick, which is also the vector of Lyme disease.
Onset of clinical signs and symptoms of acute HGE typi-
cally follow a 5- to 10-day incubation period. The acute illness
is nonspecific and often includes fever, chills, headache, and
myalgia. Abnormal laboratory findings may include leukope-
nia, thrombocytopenia, and mildly elevated liver enzymes (5).
Seventeen percent to 56% of patients with HGE are hospital-
ized, and the case-fatality rate may be 0.7%-4.9% (3,5).
Patients treated with doxycycline usually defervesce within 24
to 48 hours (5).
The acute phase of HGE is well characterized. The poten-
tial for persistent infection has been suggested but has not been
evaluated. We conducted an exploratory case-control study of
patients previously treated for HGE to assess health status,
symptoms, and changes in serologic status.
Methods
Case Definition
The Centers for Disease Control and Prevention (CDC)
HGE case definition was used. A confirmed case of HGE was
defined as any acute febrile illness with laboratory confirma-
tion consisting of 1) a fourfold or greater change in antibody
titer to Ehrlichia equi by immunofluorescence antibody (IFA)
test, 2) amplification of specific ehrlichial DNA sequences by
polymerase chain reaction (PCR), or 3) demonstration of bac-
terial microcolonies (morulae) in leukocytes together with a
single elevated titer. A probable case was defined as an acute
febrile illness with a single elevated antibody titer >1:64 or
presence of morulae (6).
Patients
Both confirmed and probable cases of HGE were included
in the case-control study. Although HGE officially became a
notifiable disease in Wisconsin on April 1, 2000, we identified
111 cases of HGE in northwestern Wisconsin through specific
surveillance activities from May 1996 to December 1998 (7).
These included 86 (77%) confirmed and 25 (23%) probable
cases. The 1996 cases were detected by laboratory-based sur-
veillance within the Marshfield Clinic system, a network that
provides health care to persons in northern and northwestern
Wisconsin. The 1997 and 1998 cases were detected through
active surveillance in a 13-county region in northwestern Wis-
consin.
We selected 225 controls from a pool of approximately
880,000 living Wisconsin residents who had received medical
care from the Marshfield Clinic regional network. Controls
were randomly selected from the same zip codes as patients
and frequency matched on age group (<19, 20-39, and 10-year
intervals for persons >40 years old) and gender. A structured
questionnaire on health status and symptoms was administered
by telephone to patients and controls. The survey consisted of
items from six domains of the Medical Outcomes Trust 36-
Item Short Form Health Survey (SF-36) (8), including ques-
tions about physical function, role limitations due to physical
health problems, bodily pain, general health, vitality (energy
vs. fatigue), and health relative to 1 year earlier. In each
domain, a higher score indicated a better health state. In addi-
tion, participants were asked if they had experienced the fol-
lowing symptoms continuously or repeatedly in the previous
year: fever, fatigue, shaking chills, sweats, muscle aches,
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headache, joint pains, muscle weakness, nausea, cough, short-
ness of breath, diarrhea, vomiting, poor appetite, or confusion.
The choice of signs and symptoms was based on known clini-
cal manifestations of acute HGE (2,5,7). 
Appropriate informed consent was obtained, and clinical
research was conducted in accordance with guidelines for
human experimentation as specified by the U.S. Department of
Health and Human Services and the Marshfield Medical
Research Foundation.
Diagnostic Methods
 Case-patients were asked to provide blood samples for
HGE serologic testing and measurement of aspartate ami-
notransferase (AST). We performed polyvalent IFA on sera
using E. equi substrate (ProtaTek International, St. Paul, MN)
and fluorescein isothiocyanate-conjugated goat anti-human
immunoglobulin (Kallestad Diagnostics, Chaska, MN) diluted
to 1:100. E. equi is closely related or identical to the agent that
causes HGE (1,9).
Statistical Analysis
Data were analyzed by using univariate logistic regression
models with calculation of odds ratios (OR) and 95% confi-
dence intervals (CI) by using SAS software (Version 6.12,
SAS Institute, Cary, NC); p values <0.05 were considered sta-
tistically significant, and all are two-sided.
Results
We enrolled 85 (77%) of 111 persons with previously
treated HGE (patients) and 102 (45%) of 225 controls. Of the
111 patients, we were unable to contact 13 (12%); 8 (7%)
refused participation; 4 (4%) had since died of causes unre-
lated to HGE; and 1 (1%) did not complete the survey. Among
the 225 controls, we were unable to contact 56 (25%); 61
(27%) declined to participate; and 6 (3%) surveys were
incomplete.
There were 73 (86%) confirmed and 12 (14%) probable
cases of HGE. Among confirmed cases, 32 (44%) were con-
firmed by serology alone; 13 (18%) by serology and poly-
merase chain reaction (PCR); 10 (14%) by PCR alone; 9
(12%) by serology, PCR, and presence of intracytoplasmic
morulae; 6 (8%) by serology and presence of morulae; and 3
(4%) by PCR and morulae. Of the 12 probable cases, 9 (75%)
had a single IFA serologic titer >64, and 3 (25%) had intracy-
toplasmic morulae identified in blood. The median age of
patients was 58 years (range 6-88 years), and the median age
of controls was 57 years (range 6-88 years); 66% of patients
and 73% of controls were male. Data on coexisting conditions
were available for all 102 controls and 39 (53%) of 73 con-
firmed cases. Comparison of the 39 cases and 102 controls
demonstrated no significant difference in the prevalence of
cancer (p=0.36), stroke (p=0.49), heart disease (p=0.89), or
diabetes (p=0.65).
For HGE patients, the median interval from illness onset to
telephone interview was 24 months (range 10-40 months).
Twelve patients had onset of HGE in 1996, 35 in 1997, and 38
in 1998. The illness was severe enough in 32 (38%) patients to
require hospitalization. All 85 enrolled patients received some
form of antibiotic treatment for acute illness. Of the 59
patients for whom we have sufficient information, 53 (90%)
were prescribed doxycycline for >7 days. The median interval
from illness onset to initiation of treatment was 7 days. Nine-
teen (22%) enrolled patients had evidence of Lyme disease
during the acute illness, either the characteristic rash, erythema
migrans (14 patients), or seroconversion to Borrelia burgdor-
feri (7 patients). Six (8%) of 76 enrolled patients tested also
seroconverted to Babesia microti after the acute illness.
Compared with controls, patients were more likely to
report the following constitutional symptoms either continu-
ously or repeatedly during the previous year: fevers, chills,
sweats, and fatigue (Table 1). Patients had lower SF-36 health
status scores for bodily pain (p=0.03) and health compared
with 1 year earlier (p=0.02), but no differences existed for
physical function, role limitations due to physical health, gen-
eral health, or vitality (Table 2). When probable cases were
excluded from analysis, confirmed patients were also more
likely to report fevers (OR 4.1, 95% CI 1.0-15.9), chills (OR
3.8, 95% CI 1.3-11.4), sweats (OR 2.8, 95% CI 1.4-5.8), and
fatigue (OR 1.7, 95% CI 1.0-3.1) during the previous year.
Confirmed cases also had lower SF-36 scores for relative
health (p=0.02), but no significant differences existed for
bodily pain, physical function, role limitations due to physical
health, general health, or vitality. When asked about their
health status relative to before infection, 39% of patients
believed their current health was “somewhat worse” or “much
worse.”
The presence of continuous or recurrent constitutional
symptoms and the duration of acute illness were not corre-
lated. Patients who were hospitalized or who started antibiot-
ics more than 14 days after onset of illness were no more likely
Table 1. Recurrent or continuous symptoms experienced during the 
preceding 12 months by human granulocytic ehrlichiosis patients and 
controls, Wisconsin, 1999
Symptom
Patients 
(N=85)
number (%)
Controls
(N=102)
number (%) OR 95% CI
Fevers 12 (14.1) 3 (2.9) 5.4 1.7-24.4
Shaking chills 16 (18.8) 5 (4.9) 4.5 1.7-14.3
Sweats 31 (36.5) 16 (15.7) 3.1 1.6-6.3
Fatigue 47 (55.3) 38 (37.3) 2.1 1.2-3.7
Confusion 16 (18.8) 12 (11.8) 1.7 0.8-4.0
Muscle weakness 27 (31.8) 30 (29.4) 1.1 0.6-2.1
Headache 21 (24.7) 13 (12.8) 1.1 0.7-1.9
Muscle aches 40 (47.1) 44 (43.1) 1.0 0.7-1.5
Joint pains 50 (58.8) 54 (52.9) 0.9 0.6-1.2
Nausea 14 (16.5) 15 (14.7) 0.8 0.5-1.4
OR = odds ratio; 95% CI = 95% confidence interval.RESEARCH
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to experience recurrent symptoms than those who received
antibiotic treatment within 14 days. Similarly, patients with 1)
a preexisting chronic illness, 2) intragranulocytic morulae in
an acute-phase blood smear, 3) laboratory evidence of concur-
rent Lyme disease or babesiosis, 4) anemia, or 5) a high acute-
or convalescent-phase reciprocal HGE IFA antibody titer
(>512) were no more likely than the other patients to experi-
ence one or more of the recurrent or continuous symptoms.
Serum specimens were submitted for serologic testing by
70 (82%) of 85 patients. The HGE IFA antibody titer remained
elevated (>1:64) in one (1.4%) of 70 specimens tested. This
patient had a very high titer after acute infection (1:2,048),
which remained elevated (1:256) 1 year later. He experienced
continuous or recurrent fatigue, vomiting, and headaches. Two
(2.9%) of 69 patients had elevated (>100 U/L) serum AST lev-
els; one complained of continuous or recurrent chills, sweats,
and fatigue.
Discussion
Our results demonstrate that some patients with treated
HGE may experience more fevers, chills, sweats, and fatigue
than controls 1-3 years after onset of illness. Some patients
also experience more bodily pain and have a poorer perception
of their health compared with 1 year ago than controls, but
they do not have any functional disability. Except for bodily
pain, these findings persisted when only confirmed cases were
included in the analysis. We found no serologic evidence to
suggest the occurrence of persistent ehrlichial infection. These
symptoms may therefore be attributed to a postinfectious syn-
drome rather than persistent or recurrent infection.
Few previous studies have evaluated the long-term sero-
logic profile of treated HGE. Results of one study of treated
HGE demonstrated that antibody titers remained elevated 11 to
14 months after onset in 5 of 10 patients tested (10). In another
study of HGE patients, not all of whom were treated, Bakken
et al. detected E. equi antibodies in 11 (46%) of 24 patients at
12 months, 4 (44%) of 9 at 18 months, and 2 patients (denomi-
nator not reported) at 30 months (5). The same researchers
found that sera from 71 (15%) of 475 asymptomatic residents
of northwestern Wisconsin contained antibodies to E. equi
(11). In our study, only 1 of 70 patients had a persistently ele-
vated antibody titer; however, specimens were collected more
than 1 year after acute onset in approximately 95% of patients,
and the geographic distribution of patients differed from that
of the Bakken study.
Animal studies and case reports have suggested the possi-
bility of chronic or recurrent HGE. Experimental ehrlichiosis
infections in dogs and horses have demonstrated the presence
of E. canis and E. equi, respectively, in tissues up to 2 months
after treatment with doxycycline (12,13). An HGE patient
from Wisconsin was one of the first anecdotal reports to sug-
gest this possibility in humans. In that case, serologic evidence
of a chronic ehrlichial infection or reinfection was identified 3
years after treatment for Lyme disease and HGE coinfection
(14). Another study from Connecticut included one patient
who had a specimen positive by PCR 7 weeks after treatment,
indicating a possible persistent ehrlichial infection. In that
study, PCR was used to demonstrate the presence of ehrlichial
DNA in the blood of some patients who were seronegative
(15). Dumler and Bakken detected HGE agent DNA by PCR 2
to 30 days after illness onset in four patients; two of them had
no HGE antibody detectable at the time (16). Compared with
the serology testing used in this study, PCR may be a more
sensitive assay in detecting late ehrlichial infection (17).
Our study used current national case definitions for HGE
(6). These criteria allow for positive PCR alone as laboratory
confirmation. Ten (14%) of the 73 confirmed HGE cases were
confirmed by positive PCR alone. However, a recent report by
the American Society of Microbiology’s Task Force on Con-
sensus Approach for Ehrlichiosis (CAFÉ) considers positive
PCR alone (without other laboratory support) to represent
probable laboratory evidence of HGE (18). If we had applied
CAFÉ criteria to our study, we would have had 63 (74%) con-
firmed and 22 (26%) probable cases of HGE.
The primary outcome measures in this study were based on
self-reported symptoms. Without laboratory confirmation of
persistent infection, recall bias should be considered as a pos-
sible explanation for the findings. Because of the severity of
their past illness and because this was not a blinded study,
HGE patients may have been more aware of their constitu-
tional symptoms and had better recall of them than controls.
Selection of controls is another potential source of bias if they
were less likely to have coexisting chronic diseases compared
with cases. However, we found no statistical difference in the
prevalence of cancer, stroke, heart disease, or diabetes
between cases and controls.
Previous studies of various infectious diseases have sug-
gested that convalescence from illness is significantly depen-
dent on the emotional state of the patient. In those studies, as
in ours, fatigue was often a persistent symptom (19-21). In a
study of recovery from influenza, Imboden noted that “delayed
recovery following acute self-limited illness occurs in persons
who respond to psychological tests in patterns characteristic of
depression-prone patients” (19). We did not collect baseline
psychological data, but the subset of HGE patients with
Table 2. Mean scores and standard errors (SE) in six domains of the 
Medical Outcomes Study 36-Item Short-Form Health Survey in 
patients and controlsa 
Domain
Patients
mean (SE)
Controls
mean (SE) p
Physical function 77 (2.3) 74 (2.8) .83
Physical health-related role 
limitations
68 (4.1) 74 (3.7) .16
Bodily pain 62 (2.9) 69 (2.5) .03
General health 59 (1.4) 59 (1.4) .64
Vitality 57 (2.4) 58 (2.1) .46
Relative health 45 (2.4) 52 (1.8) .03
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recurrent or persistent constitutional symptoms may have been
psychologically predisposed to a protracted convalescence.
In summary, we found that a subset of patients with HGE
have persistent constitutional symptoms 1-3 years after treat-
ment, without functional disability. Further research is needed
to determine whether these symptoms are related to the previ-
ous ehrlichial infection or other causes. In the absence of sero-
logic evidence of persistent infection, we believe these
symptoms are most likely due to a postinfectious syndrome.
Further studies that use PCR testing of convalescent-phase
samples would be helpful to exclude the remote possibility of
persistent Ehrlichia infection.
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